L
L.E.A.F. Pharmaceuticals
A Pharmaceuticalls Company
About L.E.A.F. Pharmaceuticals
L.E.A.F. Pharmaceuticals, founded in August 2014 by Dr. Clet Niyikiza, is a global pharmaceutical company focused on discovering and developing therapies for cancer and other diseases. The company's name is an acronym for Lifting and Empowering All Families, reflecting its mission to provide new medicines to patients worldwide, particularly in underserved regions.
Dr. Niyikiza, a native of Rwanda, brings over three decades of experience in cancer research and drug development to the company. His journey in the pharmaceutical industry includes senior roles at major corporations like GlaxoSmithKline, Eli Lilly and Company, and Merrimack Pharmaceuticals. Notably, he was involved in the development and approval of significant anti-cancer drugs such as ONIVYDE®, GEMZAR®, and ALIMTA®. His background in mathematics and statistics, with a Ph.D. from Indiana University-Bloomington, has been instrumental in his work on drug discovery and development.
L.E.A.F. Pharmaceuticals operates by researching, developing, manufacturing, and marketing pharmaceutical products for cancer, autoimmune, and infectious diseases. The company also re-engineers promising but previously failed molecules to create new, safer, or more effective medicines. Its business model revolves around the development and eventual commercialization of its drug pipeline, seeking partnerships to accelerate the availability of its novel drugs to patients. The company's activities encompass the entire drug development lifecycle, from initial research and clinical trials to manufacturing and marketing.
The company's drug pipeline includes several onco-immuno antimetabolites designed to disrupt cancer cell metabolism. Key products in development are LEAF-1401, LEAF-1701, LEAF-1702, and LEAF-1703. LEAF-1401, a liposomal formulation of pentaglutamated pemetrexed, has shown to be significantly more potent than the existing cancer drug pemetrexed in preclinical studies. In 2018, the company received positive feedback from the U.S. Food and Drug Administration (FDA) for these four lead drug candidates, providing a clear roadmap for clinical trials. One of these drugs may be eligible for an expedited registration pathway. In a significant milestone, L.E.A.F. established a subsidiary in Rwanda in 2017 to serve as a hub for biotechnology research and pharmaceutical manufacturing in Africa.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Woburn, United States
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Aug 2017 | $40M | $162M | Undisclosed | — |
Growth signals
Latest recorded traffic for L.E.A.F. Pharmaceuticals is 620 monthly website visits, up 210% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
L.E.A.F. Pharmaceuticals in the Woburn ecosystem
The L.E.A.F. Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about L.E.A.F. Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See L.E.A.F. Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








